|
GSK PLC on Monday said it has had an application to expand the use of mepolizumab for the treatment of chronic obstructive pulmonary disease accepted for review by the European Medicines Agency. Mepolizumab, sold under the brand name Nucala, is a humanized monoclonal antibody used for the treatment of severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome. The application is supported by results from the positive phase III Matinee trial, which showed a statistically significant and clinically meaningful reduction in the annualised rate of moderate/severe exacerbations with mepolizumab compared to placebo. If approved, mepolizumab could be the first biologic with monthly dosing for patients with COPD. It is not currently not approved for use in COPD in any country. COPD is a progressive and heterogeneous inflammatory lung disease that includes chronic bronchitis and/or emphysema. Shares in GSK were 0.6% lower at 1,500.00 pence each in London on Monday morning. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
